Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.49 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR7 | P34969 | 7/20 | 0.41 |
| ▸ | DRD2 | P14416 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787942 | 0.85 | CMA1 (0.51) | CMA1PFKFB4GHSRNPSR1L3MBTL1 | |
| SCHEMBL788282 | 0.85 | CMA1 (0.48) | CMA1PFKFB4GHSRNPSR1L3MBTL1 | |
| SCHEMBL10369582 | 0.83 | NPSR1 (0.50) | CMA1PFKFB4NPSR1L3MBTL1CA2 | |
| SCHEMBL1742182 | 0.80 | PFKFB3 (0.51) | CMA1PFKFB4NPSR1L3MBTL1CA2 | |
| SCHEMBL1548591 | 0.80 | NPSR1 (0.62) | CMA1PFKFB4NPSR1L3MBTL1HTR6 | |
| SCHEMBL1260774 | 0.78 | CMA1 (0.62) | CMA1PFKFB4GHSRNPSR1L3MBTL1 | |
| SCHEMBL1575935 | 0.75 | HSD11B1 (0.44) | CMA1L3MBTL1CA2 | |
| SCHEMBL13572241 | 0.75 | CMA1 (0.71) | CMA1PFKFB4GHSR | |
| SCHEMBL2614663 | 0.74 | CYP17A1 (0.42) | CMA1PFKFB4 | |
| SCHEMBL3780823 | 0.73 | CMA1 (0.84) | CMA1PFKFB4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338466-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CMA1 3161/4885PFKFB4 3049/4885GHSR 3595/4885 |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CMA1 3281/4885PFKFB4 2988/4885GHSR 3545/4885 |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CMA1 3161/4885PFKFB4 3049/4885GHSR 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.